Skip to Content Skip to Navigation

Archive for the ‘Press Releases’ Category

Euro Commission Retreats from Cloning Technology

09:50 AM

EU Report on Cloning Ignores Science and Places Future of Technology at Risk

Austin, TX–The European Commission, in releasing its October 19 report on the uses and applications of Somatic Cell Nuclear Transfer (SCNT or cloning) in livestock reproduction, demonstrated yet again complete disregard for science and the value of the technology in achieving global food security, further isolating European food producers and consumers from technology embraced around the world.  The Commission report proposes interim measures to ban cloning technology and products from clones, as well as restricting genetics from entering Europe while the Commission considers new legislation. 

 “Today’s report from the European Commission is disheartening to those who understand and realize the true value and potential of this very powerful technology,” said Mark Walton, Ph.D., president of ViaGen.  “Nowhere in the report does it mention that animal cloning can actually improve animal health.  This technology has important application in today’s livestock industry, and this proposed ban on livestock cloning in Europe further limits the ability of European animal breeders to compete in the global market, and could even impact its use worldwide.” 

 Livestock cloning using SCNT has been practiced commercially in the United States since 1998, and has been adopted widely by livestock breeders and producers since the U.S. Food and Drug Administration released its 2008 scientific risk assessment.  That assessment concluded food products from cloned cattle, pigs and goats and the products from all offspring of any cloned food species, are as safe as products from conventionally bred animals. 

 In the United States, products from the offspring of clones are in no way restricted from the marketplace, but recognizing trading partners may need time to consider their own regulatory approaches, the U.S. Department of Agriculture (USDA) asked U.S. producers to continue to refrain from sending products derived from cloned animals to the commercial marketplace.  Cloning technology providers and the U.S. industry continue to abide by the USDA request using the industry-developed supply chain management program to meet these market demands.

 “All governments must be careful so that one nation is not making de facto short-term political decisions that hinder the ability of the world’s farmers and ranchers to access this safe technology.  Cloning has the potential to improve global livestock production and increase farmer competitiveness,” Walton said.  

  “Government and private food safety authorities around the world agree the products from cloned animals and their offspring are safe, an opinion echoed three different times by the European Food Safety Authority (EFSA),” commented David Faber, DVM, president of Trans Ova Genetics.  “To blatantly disregard the science further politicizes this issue and is a disservice to consumers and livestock producers around the world.”

 Livestock cloning has proven an effective means of improving animal health and overall livestock production in an efficient and sustainable manner.  With the World Health Organization predicting a doubling of the world’s population by 2050, this technology and others like it should be made available to all producers as the global demand for animal products increases. 

 “Producers in the United States recognize the value in using this technology as another form of an assisted reproductive technology on their farms and ranches,” according to Diane Broek, general manager of Bovance.  “U.S. farmers and ranchers, livestock genetics exporters and the food industry should know we will continue to work with the U.S. government to ensure it defends our ability to use this technology as Europe contemplates these restrictive measures.”

 About Bovance (www.bovance.com): Bovance is a joint-venture between Trans Ova Genetics of Sioux Center, Iowa and ViaGen of Austin, Texas.  Bovance provides bovine cloning services and genetic opportunities to cattle producers across North America as an exclusive product offering from Trans Ova Genetics.

 About Trans Ova Genetics (www.transova.com): Founded in 1980, Trans Ova Genetics offers advanced reproductive technologies to help breeders multiply the success of their elite cattle. These technologies include embryo transfer, in vitro fertilization, sex-sorted semen, genetic preservation and cloning.  Trans Ova Genetics also offers several recipient options, including health-certified recipients, Multiplier Herd Program and a Live Calf Program.  Headquartered in Sioux Center, Iowa, Trans Ova Genetics has regional centers in Missouri and Texas, as well as several satellite stations throughout the United States.

ViaGen to Display Cloned Horses During 2010 Alltech FEI World Equestrian Games

02:50 PM

Pure Tailor Fit- cloned stallion of two-time AQHA World Champion, Tailor Fit

Come see for yourself during the 2010 Alltech FEI World Equestrian Games September 25 – October 10, 2010 at the Kentucky Horse Park in Lexington, Kentucky. Stop by the outdoor tradeshow village at the Kentucky Horse Park (booth 202) to visit ViaGen and get the latest information on cloning technology.

ViaGen has also joined forces with Kentucky Equine Sports Medicine and Rehabilitation Center (KESMARC) to display some of the industry’s most elite equine athletes and their genetic twins.

On display at KESMARC will be Pan American Games gold-medalist Sapphire alongside his cloned foal Saphir, and two-time AQHA World Racing Champion Tailor Fit and cloned stallion Pure Tailor Fit. The horses will be on display daily to the public from 9 a.m. - 5 p.m., however, private tours can be arranged.

Thursday, October 7, Olympic Equestrian Mark Watring will be on site at KESMARC with Sapphire/Saphir answering questions about cloning his gelding and the future plans for Saphir from 10 a.m. – noon and 4 – 6 p.m.

Kentucky Equine Sports Medicine and Rehabilitation Center

Located just 4 miles west of Lexington off of Route 60.
258 Shannon Run Road
Versailles, Kentucky

Early Bird Registration Deadline is July 29 for BIO 2010 Livestock Biotech Summit

12:58 PM

WASHINGTON, D.C. (July 27, 2010) – Don’t miss your chance to get the special early-bird registration rate for the 2010 Livestock Biotech Summit.  Registration is now open, and our early-bird discounts will expire Thursday, July 29, 2010.

 The first-ever Summit of its kind, scheduled for September 28-30, in Sioux Falls, S.D., will provide participants three days of cross-cutting discussions among industry, academic and government leaders.

 Program highlights include:

 - A unique workshop tailored specifically to the care of agricultural animals in research as well as an interactive presentation on the newly revised Ag Guide.

 - Lively sessions focused on genetically engineered animals and around such topics as real life case studies of products weaving their way through the regulatory process, food and biomedical applications, and funding opportunities for animal biotechnology research.

 - Dr. Reg Gomes, Vice President Emeritus of the University of California, will speak on developing global solutions through animal biotechnology. Gomes recently retired from the
University of California, where he served as Vice President of Agriculture and Natural Resources for the university-wide system, Director of the California Agricultural Experiment Station and Director of California Cooperative Extension.

 - Bruce Knight, Principal and Founder of Strategic Conservation Solutions, will give an overview of animal agriculture focusing on the increasing importance of animal care. Formerly the Undersecretary for Marketing and Regulatory Programs at USDA and Chief of USDA’s Natural Resources Conservation Service, Knight is a nationally recognized expert on conservation, agriculture, and the environment.

 - Dr. John McGlone of Texas Tech University will be coordinating the workshop on the care and use of livestock in biomedical and agricultural research. Dr. McGlone speaks globally on topics of animal welfare, sustainable animal production, animal behavior, stress physiology and humane animal care.

 - Panels of experts speaking on the “Case Study on the First Success Story on the U.S. Road to Regulatory Approval”, the “BIO GE Stewardship Program”, “New Products in the Pipeline”, “Funding Research on GE Animals”, and “Challenges for the Future”.

Who Should Attend?

  • - IACUC Members
  • - Academic & Industrial Scientists
  • - Genetic Engineering Researchers
  • - Regulators
  • - Research Animal Suppliers
  • - Drugs & Vaccine Developers/Manufacturers
  • - Serum and Blood Producers
  • - Biomedical Device Producers
  • - Animal Disease Model Developers
  • - Xenotranplantation Specialists

 

Media Registration

All programs at the Livestock Biotech Summit are open to attendance by members of the media.* Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials. Valid press credentials include:

  • Official photo identification from employing news agency
  • A by-lined story from employing news agency dated within the last six months
  • A publication masthead listing you as an editorial contributor. Freelance journalists may also apply for complimentary media registration, but must present:
  • - A signed letter on company letterhead from your assignment editor confirming your assignment to cover the event
  • - A by-lined story dated within the last six months

 

*Web-based, college, and freelance reporters are strongly encouraged to register in advance. Please note that marketing executives, sales representatives, public relations executives, analysts, consultants, authors and researchers may not register as media.

BIO Acknowledges the Support Provided by the Livestock Biotech Summit Sponsors**

Platinum Sponsors

Hematech, Inc.

South Dakota Governor’s Office of Economic Development

Trans Ova Genetics

 

Gold Sponsors

AAALAC International

Exemplar Genetics

South Dakota State University

 

Silver Sponsors

Animal & Plant Health Inspection Service (APHIS), Animal Care – USDA

University of Illinois

Sigma-Aldrich

 

Bronze Sponsors

South Dakota Biotech Association

ViaGen, Inc.

 

Additional information on multi-level sponsorship opportunities and program details can also be found here.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

BIO Debuts Livestock Biotech Summit

02:38 PM

WASHINGTON, D.C.– The Biotechnology Industry Organization (BIO) announced its newest conference, the Livestock Biotech Summit, scheduled for September 28-30, 2010, in Sioux Falls, S.D. Focused on “Developing global solutions through animal biotechnology”, the conference will include workshops on the use and care of animals in research as well as the latest applications and benefits of genetically engineered animals.

“This is the first time we’ve done a conference like this,” said Sharon Bomer Lauritsen, executive vice president of Food and Agriculture at BIO, “With all the recent advances in both biomedical and food applications, there is no better time than now to hold this important event.” 

During three days of cross cutting discussions among industry, academic and government leaders, topics such as the regulatory process for genetically engineered (GE) animals and public and private funding opportunities will be covered.  Expert panels will focus on the science and benefits of GE agricultural animals for both food and biomedical applications as well as the regulatory hurdles and other challenges to advancing the technology.

The first day and a half of the conference includes a workshop by the Institutional Animal Care and Use Committee (IACUC 101) and an interactive program and presentation on the newly revised Ag Guide. The last half of the conference switches to lively sessions around such topics as real life case studies of products weaving their way through the regulatory process and funding opportunities for animal biotechnology research.

BIO is pleased to acknowledge the support provided by the Livestock Biotech Summit sponsors, which include:
AAALAC International
Animal & Plant Health Inspection Service (APHIS), Animal Care – USDA
Hematech, Inc.
Office of Lab Animal Welfare (OLAW) – National Institutes of Health
South Dakota State University
Trans Ova Genetics
University of Illinois
ViaGen, Inc.

REGISTER NOW
Register now at www.bio.org/livestockbiotechsummit

Cloned Foal of Legendary Polo Pony Califa Arrives

10:55 AM

Austin, Texas– The cloned foal of 10-goaler Mariano Aguerre’s famed gelding, Califa, was born April 22, making him the first cloned polo pony in the world. The bay colt is an intact stallion genetically identical to Califa.

 Aguerre has not settled on a name for the colt yet, but already has big plans for him. The colt will be able pass along Califa’s superior genetics as a stallion, an opportunity that otherwise would have never existed without cloning technology. 

“I was actually surprised how much he looks like Califa,” Aguerre said. “I couldn’t believe it. The position of his neck, hind end and even expression in his face is so much like the original. I never saw Califa at that age, but he already looks like him.” 

In terms of breeding, Califa is not only a tremendous success on the field as an individual athlete; his pedigree is considered polo pony royalty.

 ”The chance to have him back as a stallion is incredible,” Aguerre said. “His mother, Luna, was one of the greatest broodmares of all time. The whole family line is very strong.”

Califa has become world renowned for his talents and earned some of the industry’s most prestigious titles, including United States Polo Association Horse of the Year in 2005. Most recently he landed a spot on the American Polo Horse Association’s Legendary Ponies list and was named the 2009 APHA Horse of the Year. He returned to Argentina last year to join Aguerre’s string for the Argentine Open.

Aguerre plans to take the colt to Argentina as a yearling and stand him at his Los Machitos operation when he reaches breeding age.


*photo courtesy of Timbercreek Veterinary Hospital

Bull’s Eye!

06:17 PM

-Cloning takes aim at hereditary diseases by expanding the gene pool of horses that are genetically “clean”.

A revolutionary breeding technique could become a powerful weapon in the arsenal to eliminate equine genetic diseases by broadening the gene pool to include the genetics of top performing geldings that are genetically “clean.” 

Since the first equine clone was foaled in 2003, cloning has been recognized as a tool that enables horses that became outstanding competitors after they were gelded to reproduce as stallions. But as scientists continue to unravel the mysteries of genetic diseases that have plagued the horse industry for decades, cloning could also help eradicate them by increasing the number of sires that are “clean” for the lethal recessive genes that carry the disease.

Like financial experts who emphasize the importance of diversification in personal investments, cloning offers a way for breeders to diversify their genetic portfolios.  Although nine equine diseases have already been linked to genetic mutations, researchers expect to identify more.

That makes breeding options and diversification even more important for breeders who not only want to produce horses that are competitive, but also won’t pass along hereditary defects to their offspring. 

“We’re just starting to peel the lid off this thing,” said Blake Russell, vice president of ViaGen, the Austin, Texas-based commercial cloning and gene-banking company that holds the patent for equine cloning. “We all know there are going to be dozens of genetic diseases out there that haven’t been identified yet. As we learn more about genetics, we’re going to find out that lots of things have a genetic root.”

Founder Effect
Hereditary disease has been found in a variety of horses. Few equine breeds are immune.

The list includes hyperkalemic periodic paralysis (HYPP), a muscle disorder that can cause tremors or paralysis in Quarter Horses, Paint Horses, and Appaloosas. Another disease, a glycogen storage disorder called polysaccharide storage myopathy (PSSM), affects Morgans, Belgians, Percherons and Warmbloods, too.

Severe combined immunodeficiency (SCID), a lethal condition that makes foals susceptible to infections, is inherited in Arabians, while recurrent exertional rhabdomyolyssis, or “tying up,” is suspected to be linked genetically to Thoroughbreds.

Scientists have traced some diseases, such as HYPP and hereditary equine regional dermal asthenia (HERDA), a debilitating condition marked by hyperextensive skin, to a specific sire. In 1992, HYPP was publicly tied to Impressive, the immensely popular American Quarter Horse stallion whose pedigree is the foundation of many halter horses. By May 2008, there had been 366,000 Impressive descendants registered with the AQHA, according to Gary Griffith, who served as executive director of AQHA registration. The report was authored by University of California at Davis geneticist Sharon Spier, D.V.M., and E.P. Hoffman of the Research Center for Genetic Medicine in Washington, D.C. 

In 2004, the western performance horse industry was rocked when HERDA was linked to Poco Bueno, a stallion whose pedigree can be found in many of the world’s top cutting and cow horses.  

HYPP and HERDA are examples of popular sire syndrome, a tendency among breeders to increase their chance of producing winners by crossing mares with proven sires of top performers. While the crosses have resulted in hundreds of champions, the down side is a concentrated gene pool in which negative inherited traits may be amplified over the years.

“Too much breeding to one animal will give the gene pool an extraordinary dose of his genes, and this will include whatever detrimental recessives he may carry, to be uncovered in later generations,” Dr. Spier said.  “This can cause future breed-related genetic disease through what is known as Founder Effect.”

By using genetic tests and reproductive techniques, such as frozen semen, embryo transfer, and cloning wisely, horse owners can effectively breed around a disease and minimize the chance of passing it on. After a genetic test for HYPP became available in 1992, AQHA officially recognized HYPP as a genetic defect and undesirable characteristic. In response to concerns by its members, the world’s largest equine breed registry passed a regulation about HYPP in 1996.

According to Rule 205, foals born in 1998 or afterward that trace back to Impressive have a statement added to their registration certificate that recommends testing for HYPP unless test results that indicate the foal is negative (N/N) for the disease are on file with AQHA.

“AQHA will test any foals that are required to be parentage verified and who trace to Impressive for HYPP prior to registering them,” said Tom Persechino, AQHA senior director of marketing. “This testing will be performed with the same DNA sample submitted to the laboratory for parentage verification.”

AQHA took the regulation one step further in 2007 when it stopped registering foals that test double positive (H/H) for HYPP. An H/H horse, which means it has an HYPP allele from each parent, will pass the gene to its offspring 100 percent of the time.

HYPP is a dominant trait, which means the disease only requires one parent to have and pass on the gene and the disease. Because of this, beginning in 2020, AQHA will not register horses that test N/H for HYPP.  

Getting the ‘look’
Ironically, the gene for some diseases, such as HYPP and HERDA, appear to give competitors an edge. In fact, the majority of halter horses in the winners’ circle trace back to Impressive, so the marketplace is a powerful incentive for horse owners to breed to them.

After the test for HYPP became available, researchers discovered the number of H/H horses had actually increased, according to a study of data submitted to the Veterinary Genetics Laboratory at UC-Davis from 1992 to 2006. The number of N/H and N/N horses remained the same, said Dr. Spier, an international expert on HYPP who presented the results at the 2006 American Association of Equine Practitioners Convention.

“There has been no decrease in the gene frequency of HYPP,” said Dr. Spier. “Because the gene frequency has not decreased over time, and is higher in elite performance horses successful at halter, this demonstrates that these horses have an advantage in the show ring for the phenotype associated with this disease.”

Successful halter people on the front lines of the industry agree.

“Breeders continue to breed to an Impressive horse because it has more potential to be a better show individual if it’s an N/H horse than if it’s an N/N horse,” said Ted Turner Jr., who has shown 66 AQHA World Champions since he began exhibiting halter horses in the mid-1970s. Turner trains at Turner Bradshaw Ranch in Thackerville, Oklahoma, where he partners with sports broadcaster and four-time Super Bowl quarterback Terry Bradshaw.

“An N/H horse has more potential to have more muscle,” Turner noted. “N/N horses are really nice, but 95 percent of the time they don’t have the cut and that extra little oomph you’re looking for. There are always exceptions to the rule.

“But I would rather have an N/H horse to show. It usually has more potential than an N/N horse to get that look you want. It’s worth the risk.”

Peter J. Cofrancesco III, whose family has bred and shown halter horses for 40 years, concurs with Turner. Located in Sparta, N.J., Peter J. Cofrancesco Jr. Farms has owned 35 AQHA World Champions, and its owner has shown 16.

“All of our horses that have been successful on a national level have bloodlines that trace back to Impressive,” said Cofrancesco, who serves on the AQHA Executive Committee. “Most of the halter horses that are winning today have physical attributes that they normally would not have if they were double negative. Everything has become so specialized and it’s so competitive that everyone is trying to breed that perfectly conformed horse.

“But if someone chooses not to incorporate the HYPP gene into their program, those horses are certainly available to them. There are a lot of mares out there with the HYPP gene, so with AQHA’s new registration rules, those mare owners are going to want to breed their mares to a stallion that is double negative.”

Breeders in every equine discipline are searching for an outcross stallion that can strengthen the breed without contributing negative traits. But that genetically clean individual might already be under the industry’s nose as a gelding that is a proven competitor.

Swimming in the pool
It happens all the time, usually when a colt is a yearling. Perhaps its pedigree isn’t a name brand because its sire is young. For whatever reason, the stallion is gelded, and it goes on to become an outstanding competitor, winning titles and setting records. But because it’s a gelding, its desirable characteristics are lost.

But what if you could bring him back as a stallion so you could propagate his genetics? Cloning provides an opportunity to do that, plus dilute popular sire syndrome, Russell said.

“Cloning is the best tool we have available today to deal with popular sire syndrome. Outstanding geldings that went on to prove themselves in competition were gelded for whatever reasons,” he explained. “Maybe they weren’t the most popular bloodline at the time, but in light of some of these recessive genetics problems, maybe those bloodlines should be resurrected and given another opportunity.

“Or maybe the colt is out of a desirable bloodline that has a negative trait, and it’s gelded because of the indictment that came with the bloodline. You probably don’t even bother to gene-test your geldings. Then the horse goes on and does fantastic. But if that gelding is tested and comes back negative, then by cloning, you can bring that animal back as a stallion.” 

“By offering animals from proven bloodlines that test negative for a disease, those animals could pass along all the desirable genetics of their bloodline without passing the genetic mutations.”

While some geneticists believe cloning will increase popular sire syndrome because it adds more individuals who have the same genetics to the gene pool, Russell maintains the opposite is true.

“My argument is exactly the opposite – the only way you move away from popular sire syndrome is to have more good sires,” he explained. “Cloning offers more options in the market. There are many examples in any discipline where there are geldings that are great candidates to be good sires after they prove themselves.”

Russell cites a clone of Tailor Fit, the two-time AQHA World Champion running horse, as an example. The 1995 bay gelding by Strawfly Special out of Silk Shirt netted $1.4 million in lifetime earnings before he was retired. Tailor Fit’s soundness was as solid as his track record, which he proved by competing through his 6-year-old year. The clone, which Russell co-owns with Betty Jane Burlin, was born on May 1, 2009.

If the clone proves himself as a sire, he would broaden the gene pool by offering an alternative to other great AQHA running horses like Dash For Cash or Peter McCue.

“Tailor Fit has to prove himself as a sire before he draws some traffic away from those horses. But if he does, then he broadens the potential, and therefore popular sire syndrome is not as big as a problem as it would have been otherwise,” Russell said.

Genetic inbreeding, which resulted in inherited diseases, occurred for centuries before cloning came on the scene.

“People say there is too much genetic inbreeding in horses now, but that was done without cloning,” said Gregg Veneklasen, D.V.M., an equine reproduction specialist who performs the embryo transfers for ViaGen. “There are two ways to eliminate genetic disease. One, breed only to those horses that are N/N, or double negative, for the disease. Or two, breed to clones of horses that are N/N, or double negative.”

Dr. George Seidel Jr., a University Distinguished professor at the Animal Reproduction and Biotechnology Laboratory at Colorado State University, believes cloning can be used to address different needs.

“One of its clear advantages is making a stallion out of a gelding,” he said. “Cloning is often thought of narrowing the gene pool and it can do that, depending on how it is used. But in terms of making a stallion out of a gelding, you’re doing the exact opposite – you’re broadening the gene pool because you’re allowing more genes to be used.”

Cloning could also be used to decrease hereditary diseases in horses, said Seidel.

“I think cloning could have a positive impact on genetic disease,” he said. “It’s a tool that can be used in that direction. I don’t know what impact it would have on the industry, but I think it would help.”

Cloning isn’t a cure-all for genetic diseases, Russell cautions.

“It isn’t the silver bullet that’s going to solve every breeding problem a breeder has,” he maintains. “But in the case of genetic diseases, it’s a technology that broadens the number of options available to breeders. Genetic diseases typically are the result of one or two popular families.

“As they say, ‘Dilution is the solution to pollution.’”

No bull
When a lethal hereditary disease prompted the American Angus Association to stop registering cattle that carried the genetic mutation, some producers turned to cloning to take up the slack.

After scientists tied arthrogryposis multiplex (AM), also known as curly calf syndrome, to a lethal recessive gene traced to a maternal grandsire, Rito 9J9 of B156, the association acted swiftly to eliminate the gene.

According to an amendment approved on Nov. 15, 2008, offspring of registered AM carrier females and bulls born on or before Dec. 31, 2009, must be DNA tested for the mutation in order to be registered. Calves of registered AM-carrier females and bulls born on or after Jan. 1, 2010, must be DNA tested and be free of the mutation to be eligible for registration.

In a nutshell, the new policy allowed animals carrying the gene to be registered through 2009. After that, no animal with the gene could be registered.

“They wanted to get the allele out of the population,” said Dr. George Seidel Jr., a reproductive physiologist at Colorado State University who also raises Angus. “After 2009, you can’t register an animal that is heterozygous (who carries only one copy of the gene). If an animal has two copies, it won’t survive. If you have one copy, you’re still out. You have to do a blood test even if there’s a possibility an animal is carrying the gene.

“The rule wasn’t particularly popular with a lot of people, partly because the heterozygote is a perfectly normal animal. But half of the offspring of heterozygote curly calf syndrome cattle will get the bad allele.”

As a result, some old bloodlines have become even more popular, and breeders have cloned some cattle to preserve their genetics and make them more available. Owners of N Bar Primrose 2424, who died when she was almost 20 years old, have made genetic copies of the cow that had a major impact on the Angus breed.

Primrose 2424′s sons include Pathfinder Sire N Bar Emulation EXT (the leading sire of registered Angus cattle for seven consecutive years), and her daughters, who brought top prices at industry sales, have been key breeding influences around the world.

“Cloned calves of Primrose 2424 are selling at public auction,” said ViaGen’s Russell. “Cloning is playing a role in helping to multiply some of the individuals that were known to be negative for lethal recessives.   

“Primrose 2424 had been owned by several people who had her biopsied, so each of those groups have been cloning her. Cloning is helping to fortify their bloodlines and preserve the genetics of a great cow.”

Express Ranches in Yukon, Oklahoma, has cloned Primrose 2424.

“We recognize the importance of producing high-quality breeding stock that is genetically pure and free from known genetic defects,” said Mark Squires, office administrator of Express Ranches. “We use all proven technologies to meet the needs of our demanding clients”.

“For example, in recognition of the known recessive defects identified in the Angus breed in the past 24 months, we have produced a few clone calves of Primrose 2424, who has a track record of producing high-quality sons and daughters. She is free from these known defects, and any Angus breeder can use more Primrose genetics in their herd.”

Continental Studbook and ViaGen Announce Cooperation on Warmblood and Thoroughbred Sport Foal Registrations

03:14 PM

The Continental Studbook and ViaGen are pleased to announce that the two companies are working together to register cloned foals produced for North America.ViaGen is recognized as the global leader in cloning technology and gene banking services. The Austin, Texas, based company has produced more cloned horses than any other company or research institution in the world. The Continental Studbook is an elite Olympic and hunter sport breeding registry modeled specifically for North America. The Eugene, Oregon, based company is an inclusive registry of high quality horses comprised of sport thoroughbreds and all top ranked warmblood breeds.

The relationship is an excellent fit for both ViaGen and the Continental Studbook. ViaGen has cloned and continues to clone some of the signficant performance and breeding horses in our sports, and the Continental Studbook is dedicated to giving domestic breeders the opportunities to produce the highest quality and best performing horses possible. Until now, the genetic contributions of many great horses were unavailable to breeders. Colts born at ViaGen can now be registered in the Continental Studbook and eventually can be licensed for breeding provided stallion requirements are met. High performance mares which may have competed through their prime reproductive years can now produce.

The Continental Studbook Future stallions can service the largest possible domestic mare population with limited overhead for their owners, and mare owners can use these stallions without geopolitical restrictions. Traditional breeding methods will continue to represent the vast majority of horse registrations, but the Continental Studbook is proud to support access to important genes for domestic breeders who choose to use them. Cloned stallions are now used for breeding in Europe, and the Continental Studbook is pleased to bring the same opportunities to breeders in North America.

For more information about registration, visit www.continentalstudbook.com

Stem Cell Research to Revolutionize Equine Lameness Therapies

01:51 PM

Austin, Texas –In a breakthrough for the performance horse industry, ViaGen, Inc. is partnering with the Monash Institute of Melbourne, Australia, to harness equine stem cells to repair tendon, ligament, cartilage and bone damage in horses.

Dr. Paul Verma of the Monash Institute of Medical Research is working to develop equine embryonic stem cell lines, with the goal of creating a ‘bank’ of stem cells genetically matched to individual horses.

Tendon, ligament and cartilage injuries can range from minor inflammation to complete rupture, which can result in permanent lameness and the end of a horse’s competitive life. Once a horse has damaged a tendon or ligament, the risk of re-injury is very high. Bone damage varies in severity, with the most serious cases resulting in the euthanasia of the injured horse.

Stem cells have the potential to reverse this damage.

“We have developed techniques to derive stem cells from horse embryos, and through a pilot study, we have successfully created a number of equine embryonic stem cell lines,” Dr. Verma said. “The next step will be to look at using these stem cell lines to regenerate tendon, ligament, cartilage and bone cells. Once the stem cells can be coaxed into ‘becoming’ the appropriate tissue cells, they can be transplanted to replace the damaged tissue.”

The natural source of therapeutic cells developed by Dr. Verma will be recognized by a horse’s immune system as its own; there will be no risk of the tissue rejection that can occur with conventional transplants.

“The risk of rejection will be overcome because the new tissue will genetically match the horse receiving treatment,” said Dr. Irina Polejaeva, ViaGen’s Chief Scientific Officer.

Having ready access to a bank of individually-tailored equine cells will greatly speed up the rehabilitation process for injured horses, and give them a chance to resume activities that might otherwise have become impossible.

Current stem cell therapies involve aspirating adipose (fat) derived cells or bone marrow cells from the injured horse. The cells are then sent to a laboratory and grown into the required tissue cells — a process that can take up to three weeks. The use of equine embryonic stem cells guarantees to revolutionize equine lameness therapies.

Embryonic Stem Cell Advantages:

1. Flexible: Have the potential to make any cell type.

2. Immortal: One embryonic stem cell line can potentially provide an endless supply of cells with defined characteristics.

3. Availability: Unlimited production of embryos through somatic cell nuclear transfer process.

Current Stem Cell Technique Disadvantages:

1. Limited quantity-  Can be difficult to obtain in large numbers.

2. Finite- Do not live as long as embryonic stem cells in culture.

3. Less flexible- Difficult to reprogram to form other tissue types.

 

About:

Monash Institute of Medical Research

The Monash Institute of Medical Research was established in 1991 by Emeritus Professor David de Kretser AC, the Governor of Victoria, Australia. Since then, the Institute has pioneered research into the characterization and application of stem cells; the cause and treatment of inflammation and cancer; and the improvement of women’s, men’s and children’s health.

Dr. Paul Verma

Dr Paul Verma is renowned internationally for his research into reprogramming somatic cells and the isolation and characterization of embryonic and adult stem cells. His overarching research aim is to produce autologous (patient-specific) stem cells, using cell reprogramming techniques such as somatic cell nuclear transfer and iPS cell technology that are clinically relevant and transplantable into humans. He has published many scientific papers and edited a book on transgenesis, cloning and stem cells. He is listed as principal inventor on eight granted and provisional patents in the field of cell reprogramming and stem cells.

ViaGen merges with Start Licensing

11:59 AM

FOR IMMEDIATE RELEASE

Austin, Texas – ViaGen, Inc. announced today its merger with Start Licensing, Inc. (Start). ViaGen is the leading global livestock cloning and genomics company. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Foundation for the cloning of Dolly the sheep.

The merger cements ViaGen’s dominance in the emerging animal cloning field by combining animal cloning expertise and the necessary IP all under one roof.

“We will continue to offer our clients superior livestock cloning services,” said ViaGen President Mark Walton, Ph.D., “and now also look forward to enabling innovative partners to utilize these technologies through licensing with Start.” Nuclear transfer technologies have applications not only in animal cloning but also in therapeutic protein production, xenotransplantation, and biomedical animal modeling.”

Under the terms of the merger, ViaGen acquired the shares of Start held by Geron Corporation (Nasdaq:GERN) of Menlo Park, California. and Exeter Life Sciences of Phoenix, Arizona, in exchange for equity in ViaGen. Start will continue to operate as a wholly-owned subsidiary of ViaGen.

About Start Licensing

Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Foundation (formerly Roslin Institute) for the cloning of Dolly the sheep. Start’s licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.

European Food Safety Authority Reaffirms Cloning-Related Food Safety

04:19 PM

WASHINGTON, D.C. (July 24, 2008) – The European Food Safety Authority (EFSA) announced today its final scientific opinion that food from cloned cattle and pigs is safe, and there are no implications of animal cloning on the environment. Key findings of the EFSA Scientific Committee are:

There is no indication that differences exist in terms of food safety for meat and milk of clones and their progeny compared with those from conventionally bred animals.

Somatic cell nuclear transfer, or SCNT (the most common technique used to clone animals) results in the production of healthy cattle and pig clones, and healthy offspring that are similar to their conventional counterparts based on parameters such as physiological characteristics, demeanor and clinical status.

From the data collected, no environmental impact is foreseen.

Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO) issued the following statement in response to the scientific opinion released today by EFSA:

“BIO supports the key safety findings of EFSA’s scientific opinion, which concludes that meat and milk from livestock clones and their offspring are safe, and are no different than foods from livestock produced through conventional breeding. EFSA’s findings are consistent with the U.S. Food and Drug Administration’s (FDA) January 2008 risk assessment on animal cloning, and the worldwide scientific consensus that livestock cloning is safe.

“Consumers benefit from cloning technology because the offspring of clones will produce better meat and milk products. This decision affirms the global scientific agreement that foods from livestock clones and their offspring are completely safe to eat.

“Cloning is a breeding technology that helps farmers and ranchers produce healthier animals. Animal clones are an exact genetic copy of an existing animal, a ‘twin’ born at a different time. The offspring of cloned animals are produced through conventional breeding, and their lineage gives them enhanced genetic traits.

“The primary goal of farmers and ranchers is production of healthy animals and this technology, like many others, advances that goal. As noted by EFSA and the FDA, there are no unique animal health risks associated with livestock cloning, as compared with other assisted reproductive technologies. In fact, cloning offers the potential to significantly improve health and well-being of the herd because cloned animals will be used to breed healthier offspring.

“Now is the time to invest in this and other science-based solutions to achieve an improved, sustainable and reliable food supply. Cloning is just one example of how agricultural biotechnology can provide those solutions to consumers, farmers and food processors and retailers around the world.”

In February 2007, the European Food Safety Authority (EFSA) was asked by the European Commission to provide a scientific opinion on the food safety, animal health, animal welfare and environmental implications of animal clones, obtained through the SCNT technique, of their progeny and of the products obtained from those animals. The final opinion also follows public consultation on a draft opinion issued earlier this year. The final opinion is posted online at: www.efsa.europa.eu.

For more information on cloning, visit www.clonesafety.org.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.